344 results on '"Gill, Harinder"'
Search Results
2. A randomized, double-blind, placebo-controlled phase 3 study to assess efficacy and safety of ropeginterferon alfa-2b in patients with early/lower-risk primary myelofibrosis
3. Loss of symmetric cell division of apical neural progenitors drives DENND5A-related developmental and epileptic encephalopathy
4. Management of classical Philadelphia chromosome-negative myeloproliferative neoplasms in Asia: consensus of the Asian Myeloid Working Group
5. Allogeneic haematopoietic stem cell transplantation for myelofibrosis: prognostic indicators and the role of JAK2V617F measurable-residual disease monitoring by droplet-digital polymerase chain reaction
6. Acute promyelocytic leukaemia: population-based study of epidemiology and outcome with ATRA and oral-ATO from 1991 to 2021
7. Genome-wide sequencing and the clinical diagnosis of genetic disease: The CAUSES study
8. Implications of Clonal Hematopoiesis in Hematological and Non-Hematological Disorders.
9. CD3+CD4+ lymphoid neoplasm: diagnostic clues for plasmablastic lymphoma instead of peripheral T-cell lymphoma
10. Safe and effective treatment of venous Thromboembolism associated with Cancer: focus on direct Oral Anticoagulants in Asian patients
11. Responsiveness of Output & Prices to Monetary & Fiscal Shocks in India
12. Characteristics and predictors of early hospital deaths in newly diagnosed APL: a 13-year population-wide study
13. Clinical delineation, sex differences, and genotype–phenotype correlation in pathogenic KDM6A variants causing X-linked Kabuki syndrome type 2
14. Idiopathic splenomegaly in childhood and the spectrum of RAS-associated lymphoproliferative disease: a case report
15. Evolving landscape of JAK inhibition in myelofibrosis: monotherapy and combinations
16. Next-generation sequencing with a 54-gene panel identified unique mutational profile and prognostic markers in Chinese patients with myelofibrosis
17. Risk of viral reactivation in patients with occult hepatitis B virus infection during ruxolitinib treatment
18. ORAL arsenic trioxide to combat acute promyelocytic leukaemia
19. Congenital heart defects : a clinical and genetic analysis
20. Editorial: Acute promyelocytic leukemia - towards a chemotherapy-free approach to cure in all patients, Volume II
21. Targeting and Monitoring Acute Myeloid Leukaemia with Nucleophosmin-1 (NPM1) Mutation
22. Additional file 1 of Acute promyelocytic leukaemia: population-based study of epidemiology and outcome with ATRA and oral-ATO from 1991 to 2021
23. Additional file 3 of Acute promyelocytic leukaemia: population-based study of epidemiology and outcome with ATRA and oral-ATO from 1991 to 2021
24. Additional file 2 of Acute promyelocytic leukaemia: population-based study of epidemiology and outcome with ATRA and oral-ATO from 1991 to 2021
25. Additional file 4 of Acute promyelocytic leukaemia: population-based study of epidemiology and outcome with ATRA and oral-ATO from 1991 to 2021
26. Additional file 7 of Acute promyelocytic leukaemia: population-based study of epidemiology and outcome with ATRA and oral-ATO from 1991 to 2021
27. Additional file 8 of Acute promyelocytic leukaemia: population-based study of epidemiology and outcome with ATRA and oral-ATO from 1991 to 2021
28. Additional file 6 of Acute promyelocytic leukaemia: population-based study of epidemiology and outcome with ATRA and oral-ATO from 1991 to 2021
29. Additional file 5 of Acute promyelocytic leukaemia: population-based study of epidemiology and outcome with ATRA and oral-ATO from 1991 to 2021
30. Additional file 9 of Acute promyelocytic leukaemia: population-based study of epidemiology and outcome with ATRA and oral-ATO from 1991 to 2021
31. Correction: Gill, H. Lysine-Specific Demethylase 1 (LSD1/KDM1A) Inhibition as a Target for Disease Modification in Myelofibrosis. Cells 2022, 11, 2107
32. Oral arsenic trioxide for treating acute promyelocytic leukaemia: Implications for its worldwide epidemiology and beyond
33. Efficacy and Safety of Ropeginterferon Alfa-2b for Pre-Fibrotic Primary Myelofibrosis and DIPSS Low/Intermediate-1 Risk Myelofibrosis
34. A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Advanced Myelofibrosis (MF): Updated Results and Genomic Analyses
35. A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Essential Thrombocythemia (ET)
36. A novel tescalcin-sodium/hydrogen exchange axis underlying sorafenib resistance in FLT3-ITD+ AML
37. The Development and Clinical Applications of Oral Arsenic Trioxide for Acute Promyelocytic Leukaemia and Other Diseases
38. SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia
39. Lysine-Specific Demethylase 1 (LSD1/KDM1A) Inhibition as a Target for Disease Modification in Myelofibrosis
40. Prevalence and architecture of de novo mutations in developmental disorders
41. Disseminated infections with talaromyces marneffei in non-AIDS patients given monoclonal antibodies against CD20 and Kinase inhibitors
42. Cytomegalovirus retinitis complicating combination therapy with rituximab and fludarabine
43. Epigenetic Silencing of PTEN and Epi-Transcriptional Silencing of MDM2 Underlied Progression to Secondary Acute Myeloid Leukemia in Myelodysplastic Syndrome Treated with Hypomethylating Agents
44. MO846: Temporal Evolution of Humoral Response in Haemodialysis Patients Vaccinated With Two Doses of CHADOX1-S Vaccine
45. Single-Nucleotide Variations, Insertions/Deletions and Copy Number Variations in Myelodysplastic Syndrome during Disease Progression Revealed by a Single-Cell DNA Sequencing Platform
46. Editorial: Acute Promyelocytic Leukemia — Towards A Chemotherapy-Free Approach to Cure in All Patients
47. Breakthrough invasive fungal diseases during echinocandin treatment in high-risk hospitalized hematologic patients
48. FLT3 internal tandem duplication in acute promyelocytic leukemia: central nervous system relapse
49. Torsade de Pointes during oral arsenic trioxide therapy for acute promyelocytic leukemia in a patient with heart failure
50. A Phase 2 Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Advanced Myelofibrosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.